|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Leukemia | |||||
| Lymphoma | |||||
| Precancerous/Nonmalignant Condition | |||||
| 2 | Additional conditions recognized in this trial | ||||
| Lymphoma, Non-Hodgkin | |||||
| Multiple Myeloma | |||||
| Neoplasms, Plasma Cell | |||||
| Precancerous Conditions | |||||
| 3 | More general conditions related to this trial | ||||
| Blood Protein Disorders | |||||
| Cardiovascular Diseases | |||||
| Hematologic Diseases | |||||
| Hemorrhagic Disorders | |||||
| Hemostatic Disorders | |||||
| Immune System Diseases | |||||
| Immunoproliferative Disorders | |||||
| Lymphatic Diseases | |||||
| Lymphoproliferative Disorders | |||||
| Neoplasms | |||||
| Neoplasms by Histologic Type | |||||
| Paraproteinemias | |||||
| Vascular Diseases | |||||
| 4 | Interventions listed in this trial | ||||
| omega-3 fatty acids | |||||
| 5 | Sponsors listed in this trial | ||||
| Cancer and Leukemia Group B | |||||
| National Cancer Institute (NCI) | |||||